8-K: Avalo Therapeutics Highlights Best-in-Class Potential of AVTX-009 for Hidradenitis Suppurativa in New Investor Presentation

Avalo Therapeutics, Inc. (AVTX) released an updated investor presentation highlighting its lead compound AVTX-009 for hidradenitis suppurativa and its financial runway into 2028.

Summary

• Avalo Therapeutics is advancing AVTX-009, an anti-IL-1 monoclonal antibody, for immune-mediated inflammatory diseases, with a primary focus on hidradenitis suppurativa (HS).
• AVTX-009 is designed to be a best-in-class and best-in-disease treatment for HS, a chronic inflammatory skin disease with significant unmet needs.
• The Phase 2 LOTUS trial for AVTX-009 in HS is currently enrolling patients, with topline data expected mid-2026.
• The HS market is projected to grow to over $10 billion by 2035.
• Avalo Therapeutics has an expected cash runway into 2028, with approximately $125 million cash as of March 31, 2025.
• The company's management team has over 200 years of combined experience in biotech/pharma.
• AVTX-009 has potential for indication expansion into other IL-1 driven immune-mediated inflammatory diseases like arthritis and inflammatory bowel disease.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook on the company's lead asset, its market potential, and financial stability, emphasizing future growth and clinical milestones without disclosing any significant setbacks or negative financial results.

Positives

• AVTX-009 has potential for a best-in-class and best-in-disease profile in hidradenitis suppurativa (HS) due to its 15x higher affinity and longer half-life compared to lutikizumab.
• The HS market is projected to grow substantially to over $10 billion by 2035, indicating a significant commercial opportunity.
• Avalo Therapeutics has an expected cash runway into 2028, providing financial stability for ongoing clinical development.
• The Phase 2 LOTUS trial for AVTX-009 in HS is actively enrolling patients, with topline data anticipated by mid-2026.
• The company is led by a strong management team with over 200 years of combined experience in product development and commercialization.
• Preclinical and clinical evidence supports IL-1 (not IL-1β) as a dominant immunoregulator in HS, which AVTX-009 specifically targets.
• Clinical benefit in HS has been observed with other anti-IL-1 drugs, validating the mechanism of action.
• AVTX-009 has demonstrated a well-tolerated and favorable safety profile in previous Phase 1 and Phase 2 trials involving 245 patients.
• The potency and half-life of AVTX-009 are expected to support less frequent dosing, potentially up to every four weeks (Q4W), in HS and other indications.
• There is broad potential for indication expansion of AVTX-009 into other IL-1 driven diseases, including various forms of arthritis and inflammatory bowel disease.

Risks

• Risks associated with the integration of AVTX-009 into Avalo's operations.
• Uncertainties regarding drug development costs, timing of trial results, and other risks, including reliance on investigators and patient enrollment in clinical trials.
• Reliance on key personnel for continued operations and success.
• Regulatory risks associated with drug approval processes.
• General economic and market risks and uncertainties, including those caused by geopolitical events such as the war in Ukraine and the Middle East.
• Other risks detailed in Avalo's filings with the Securities and Exchange Commission.

Future Outlook

Avalo Therapeutics expects topline data from its Phase 2 LOTUS trial in hidradenitis suppurativa by mid-2026, with plans to initiate a pivotal program in 2027, pending positive Phase 2 results. The company projects the global HS market to exceed $10 billion by 2035, driven by increased diagnosis and treatment. Avalo also anticipates exploring additional immunology indications for AVTX-009, leveraging its broad potential in IL-1 driven diseases, and maintains an expected cash runway into 2028.

Management Comments

• Avalo Therapeutics is advancing the next-generation of IL-1 inhibition for immune-mediated inflammatory diseases.
• The management team has a proven track record of successful leadership, product development, and commercialization in pharma and biotech.
• Avalo is currently assessing additional immunology indications for investment.

Industry Context

The document positions AVTX-009 within the competitive landscape of hidradenitis suppurativa (HS) treatments, highlighting the significant unmet need due to incomplete response and loss of response to current anti-TNF (e.g., Humira) and anti-IL-17 (e.g., Cosentyx, Bimzelx) therapies. It emphasizes IL-1 as a dominant immunoregulator in HS, suggesting AVTX-009's specific targeting of IL-1 could offer superior efficacy compared to existing or other pipeline treatments. The projected growth of the HS market to over $10 billion by 2035 underscores the substantial commercial opportunity within this therapeutic area, driven by increased recognition and treatment of the disease.

Comparison to Industry Standards

• AVTX-009 is highlighted as having 15x higher affinity and a longer half-life than AbbVie's lutikizumab (an IL-1α/β targeting monoclonal antibody), potentially predictive of higher efficacy and less frequent dosing.
• Lutikizumab demonstrated comparable efficacy to market leaders (e.g., Humira, Cosentyx) and pipeline therapeutics (e.g., Incyte's povorcitinib, UCB's sonelokimab, UCB's bimekizumab) in a refractory HS population (71% Hurley stage III) that had already failed anti-TNF therapy.
• Bermekimab, an IL-1β specific monoclonal antibody, performed no better than placebo in a Phase 2 study with an adalimumab (TNF inhibitor) comparator arm, suggesting that IL-1β specificity alone may not be as effective as IL-1 targeting in HS.
• Current anti-TNF and anti-IL-17 biologic therapies for HS have limited efficacy, with a large proportion of patients still reporting significant and life-disrupting symptoms, indicating a persistent unmet need that AVTX-009 aims to address.
• IL-1 targeting therapies are approved in other inflammatory conditions such as rheumatoid arthritis and acute gout flare (e.g., Ilaris, Kineret) and have shown benefits in cardiovascular events (CANTOS study with canakinumab) and osteoarthritis, providing established clinical proof of concept for the IL-1 mechanism.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through successful clinical development of AVTX-009 and significant market growth in hidradenitis suppurativa.
• Patients: Potential for a new, more effective treatment option for hidradenitis suppurativa, addressing the current unmet needs of incomplete response and loss of response to existing therapies.
• Healthcare Providers: A new therapeutic option to consider for managing hidradenitis suppurativa patients, potentially offering improved outcomes and dosing convenience.

Next Steps

• Continue enrollment in the Phase 2 LOTUS trial for hidradenitis suppurativa.
• Anticipate topline data readout from the Phase 2 LOTUS trial by mid-2026.
• Initiate a pivotal program in 2027, pending positive Phase 2 readout.
• Assess additional immunology indications for investment and potential expansion of AVTX-009's use.

Key Dates

Recommendation

Keywords

Avalo Therapeutics, AVTX, AVTX-009, Hidradenitis Suppurativa, HS, IL-1, Interleukin-1, Monoclonal Antibody, mAb, Clinical Trial, Phase 2, LOTUS trial, Biologics, Dermatology, Inflammatory Diseases, Autoimmune, Biotech, Pharmaceutical, Drug Development, Investor Presentation